This inventor holds 2 USPTO granted patents and 2 published patent applications and 1 EPO patent. Top assignee: Amabiotics. Active years: 2020-2023.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2020-2023
Title: Innovator Spotlight: Patrice Garnier
Introduction: Patrice Garnier is a notable inventor based in Venice, Italy, recognized for his contributions to scientific advancements in treating diseases linked to mitochondrial dysfunction. With a keen focus on developing effective compounds, Garnier's work has the potential to contribute significantly to the field of medicine.
Latest Patents: Garnier holds a patent for compounds designed to treat diseases associated with mitochondrial dysfunction. The patent encompasses a specific compound formula, which is applicable for the prevention or treatment of such diseases, along with its pharmaceutically acceptable salts and hydrates. This innovation reflects his dedication to improving healthcare outcomes through scientific research.
Career Highlights: As an inventor, Patrice Garnier has demonstrated a profound commitment to advancing biomedical technologies. His work at Amabiotics, where he continues to explore the intersections of biotechnology and medicine, showcases his role in pioneering new therapeutic avenues that could address challenging health issues.
Collaborations: Throughout his career, Garnier has collaborated with esteemed associates, including Antoine Danchin and Agnieszka Sekowska. These partnerships exemplify the collaborative nature of innovation, where diverse expertise can lead to groundbreaking discoveries in science and technology.
Conclusion: Patrice Garnier’s contributions to the field of mitochondria-associated disease treatment highlight the critical impact of inventive minds in healthcare. As he continues to work at Amabiotics, his ongoing efforts in research and development may pave the way for new therapeutic strategies that benefit countless individuals facing mitochondrial disorders.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile